Results 201 to 210 of about 47,495 (266)

Therapeutic approaches for liver fibrosis/cirrhosis by targeting pyroptosis. [PDF]

open access: yesOpen Life Sci
Qiao G   +6 more
europepmc   +1 more source

Nano‐plastics disrupt systemic metabolism by remodeling the bile acid–microbiota axis and driving hepatic–intestinal dysfunction

open access: yesiMeta, EarlyView.
The pervasiveness of microplastic pollution poses a growing health risk, yet its long‐term metabolic consequences remain poorly defined. Here, we exposed mice to polyethylene terephthalate nanoparticle (NP) and combined histopathology, biochemistry, metabolomics, and metagenomics to resolve their interactions.
Yi Zhang   +11 more
wiley   +1 more source

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

open access: yesiNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong   +5 more
wiley   +1 more source

Inflammasome activation contributes to cisplatin resistance in ovarian cancer. [PDF]

open access: yesJ Ovarian Res
de Souza JC   +6 more
europepmc   +1 more source

Sequential ultrasound‐driven dynamic control of macrophage polarization combined with hydrogel for mechano‐chemical synergistic tissue repair

open access: yesInterdisciplinary Medicine, EarlyView.
This study presents an innovative therapeutic strategy that integrates sequential ultrasound therapy with an injectable oxidized dextran‐metformin (ODE‐Met) hydrogel to dynamically regulate macrophage polarization and promote angiogenesis for inflamed tissue repair.
Fulong Man   +12 more
wiley   +1 more source

Inflammatory bowel disease and metabolic reprogramming: From pathological mechanisms to targeted interventions

open access: yesInterdisciplinary Medicine, EarlyView.
This review explores the role of metabolic reprogramming in inflammatory bowel disease (IBD) by focusing on immune and epithelial cell metabolism, microbial metabolites, and their impact on inflammation. It discusses emerging metabolic therapies and emphasizes the importance of personalized microbiota‐targeted approaches to improve clinical outcomes in
Zemin Tian   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy